Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

1.04
-0.0600-5.45%
Pre-market: 1.050.0098+0.94%08:27 EDT
Volume:5.66M
Turnover:5.91M
Market Cap:187.29M
PE:-2.57
High:1.10
Open:1.10
Low:1.02
Close:1.10
52wk High:6.88
52wk Low:1.02
Shares:180.09M
Float Shares:132.00M
Volume Ratio:1.23
T/O Rate:4.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:1.13
PE(LYR):-2.47

Loading ...

Compass Therapeutics Chief Accounting Officer Neil Lerner Acquires 2,500 Common Shares Worth $2,850

Reuters
·
Sep 25

Compass Therapeutics Shares Drop After Downgrade From Wedbush

MT Newswires Live
·
Sep 24

Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum

TIPRANKS
·
Sep 23

Canaccord Genuity Reaffirms Their Buy Rating on Compass Therapeutics (CMPX)

TIPRANKS
·
Sep 23

Compass Therapeutics Price Target Cut to $12.00/Share from $24.00 by HC Wainwright & Co.

Dow Jones
·
Sep 23

Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5

MT Newswires Live
·
Sep 23

Compass Therapeutics price target lowered to $4 from $10 at Citizens

TIPRANKS
·
Sep 23

US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals

Reuters
·
Sep 23

Compass Therapeutics Inc. : Guggenheim Cuts Target Price to $4 from $8

THOMSON REUTERS
·
Sep 23

Compass Therapeutics Inc. : Wedbush Cuts to Neutral from Outperform; Cuts Target Price to $1 from $5

THOMSON REUTERS
·
Sep 23

Compass Therapeutics downgraded to Neutral from Outperform at Wedbush

TIPRANKS
·
Sep 23

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 23

Compass Therapeutics (CMPX) was downgraded to a Hold Rating at LifeSci Capital

TIPRANKS
·
Sep 23

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Compass Therapeutics Faces FDA Pushback on Tovecimig Trial

TIPRANKS
·
Sep 22

Compass Falls After FDA Recommends Fresh Trial Before Marketing Application Submission

Reuters
·
Sep 22

Compass Therapeutics Says FDA Urges Survival-Benefit Trial Before Tovecimig BLA in Biliary Tract Cancer

Reuters
·
Sep 22

Compass Therapeutics - to Further Engage with FDA on Bla Submission for Tovecimig

THOMSON REUTERS
·
Sep 22

Compass Therapeutics - Does not Believe New Trial is Warranted Before Bla Submission for Tovecimig

THOMSON REUTERS
·
Sep 22

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

THOMSON REUTERS
·
Sep 22